Nuvation Bio Chief Regulatory Officer Kerry Wentworth's Stock Transactions

This Form 4 filing reports significant stock transactions by Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio Inc. (NUVB), on April 6, 2026. Wentworth exercised 200,000 stock options at exercise prices of $1.87 and $1.94 per share, acquiring 200,000 shares of Class A Common Stock. Simultaneously, she sold 200,000 shares at a weighted average price of $4.5178 per share (ranging from $4.44 to $4.64) pursuant to a 10b5-1 trading plan established on December 4, 2025. Following these transactions, her direct holdings decreased from 253,000 shares to 53,000 shares. The options exercised had expiration dates in 2033 and 2034, with vesting schedules tied to service dates in 2023 and 2024. The net effect was a substantial reduction in direct share ownership while realizing gains from option exercises and subsequent sales.